{"nctId":"NCT01580293","briefTitle":"A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A","startDateStruct":{"date":"2012-04-23","type":"ACTUAL"},"conditions":["Hemophilia A"],"count":145,"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","interventionNames":["Biological: BAY94-9027"]},{"label":"Arm 2","type":"EXPERIMENTAL","interventionNames":["Biological: BAY94-9027"]},{"label":"Arm 3","type":"EXPERIMENTAL","interventionNames":["Biological: BAY94-9027"]},{"label":"Arm 4","type":"EXPERIMENTAL","interventionNames":["Biological: BAY94-9027"]}],"interventions":[{"name":"BAY94-9027","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male; 12-65 years of age\n* Subjects with severe hemophilia A\n* Previously treated with factor VIII for a minimum of 150 exposure days\n\nExclusion Criteria:\n\n* Inhibitors to FVIII (current evidence or history)\n* Any other inherited or acquired bleeding disorder in addition to Hemophilia A\n* Platelet count \\< 100,000/mm3\n* Creatinine \\> 2x upper limit of normal or AST/ALT (aspartate aminotransferase/alanine aminotransferase) \\> 5x upper limit of normal","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Number of Total Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A, Main Trial","description":"Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds. A participant who had the one-time increase in dose frequency was regarded as rescued. A rescue bleed was a bleed that occured after the dose frequency was increased. Rescue bleeds and periods were not considered for the annualized bleeding rate (ABR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.42","spread":null},{"groupId":"OG001","value":"4.11","spread":null},{"groupId":"OG002","value":"1.93","spread":null},{"groupId":"OG003","value":"1.93","spread":null},{"groupId":"OG004","value":"3.85","spread":null},{"groupId":"OG005","value":"2.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Number of Joint Bleeds, Trauma, Spontaneous Bleeds in On-demand Treatment Arm (Weeks 0 -36) and in Each Prophylaxis Arm (Weeks 10 - 36, Excluding Rescue Bleeds) - Part A","description":"A participant who had the one-time increase in dose frequency was regarded as rescued. A rescue bleed was a bleed that occured after the dose frequency was increased. Rescue bleeds and periods were not considered for the ABR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.34","spread":null},{"groupId":"OG001","value":"4.01","spread":null},{"groupId":"OG002","value":"1.93","spread":null},{"groupId":"OG003","value":"1.86","spread":null},{"groupId":"OG004","value":"1.92","spread":null},{"groupId":"OG005","value":"1.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.09","spread":null},{"groupId":"OG001","value":"1.98","spread":null},{"groupId":"OG002","value":"0.00","spread":null},{"groupId":"OG003","value":"0.00","spread":null},{"groupId":"OG004","value":"0.00","spread":null},{"groupId":"OG005","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.29","spread":null},{"groupId":"OG001","value":"3.87","spread":null},{"groupId":"OG002","value":"0.00","spread":null},{"groupId":"OG003","value":"0.00","spread":null},{"groupId":"OG004","value":"1.93","spread":null},{"groupId":"OG005","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Annualized Number of Total Bleeds in On-demand Treatment Arm and in Each Prophylaxis Arm, Part A, Extension","description":"Annualized number of total bleeds was defined as the annualized sum of spontaneous bleeds and trauma bleeds.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.09","spread":null},{"groupId":"OG001","value":"1.57","spread":null},{"groupId":"OG002","value":"1.17","spread":null},{"groupId":"OG003","value":"0.65","spread":null},{"groupId":"OG004","value":"3.10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Developed Human Coagulation Factor VIII (FVIII) Inhibitor - Part A","description":"FVIII inhibitor testing was done according to the Nijmegen modified Bethesda assay. A positive inhibitor test was defined with a threshold of â‰¥0.6 Bethesda unit (BU) at the central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Bleeds Requiring 1, 2 or >= 3 Infusions to Control the Bleed - Part A","description":"Number of bleeds requiring 1, 2 or \\>= 3 infusions to control the bleeding","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":null},{"groupId":"OG001","value":"262","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Bleeds According to Locations - Part A","description":"Bleed locations were categorised as joint, muscle, skin/mucosa, internal, others and missing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"303","spread":null},{"groupId":"OG001","value":"235","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Bleeds Over Time Since Previous Prophylaxis Infusion - Part A","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Bleeds According to Participant's Assessment of Response to Treatment - Part A","description":"Response to treatment was assessed by participant as excellent, good, moderate, poor or missing during Part A of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":null},{"groupId":"OG001","value":"256","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Recombinant Human Factor VIII (rFVIII) Usage Expressed as Total Dose Per Kilogram Per Year - Part A","description":"For prophylaxis patients, the dose is related to all infusions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1518.5","spread":null},{"groupId":"OG001","value":"4421.4","spread":null},{"groupId":"OG002","value":"3314.4","spread":null},{"groupId":"OG003","value":"3482.9","spread":null},{"groupId":"OG004","value":"3338.7","spread":null},{"groupId":"OG005","value":"3421.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion - Part A","description":"For prophylaxis patients, the dose per infusion related to prophylaxis infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"39.2","spread":null},{"groupId":"OG002","value":"30.6","spread":null},{"groupId":"OG003","value":"45.3","spread":null},{"groupId":"OG004","value":"59.0","spread":null},{"groupId":"OG005","value":"46.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring an Increase in Dose Frequency, or Dose Increase, During Weeks 10 to 36 - Part A","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Surgeries According to Physician's Assessment of Adequacy of Hemostasis in Major Surgery - Part B","description":"Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill. Adequacy of hemostasis was assessed as excellent, good, moderate or poor, by the surgeon or interventionalist during Part B of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram Per Infusion for Major Surgery - Part B","description":"Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill. Total dose per kilogram per Infusion was expressed in international units per kilogram per infusion (IU/kg/infusion).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions for Major Surgery - Part B","description":"Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.rFVIII usage expressed as number of infusions and IU/kg per year, as well as IU/kg per event (surgery) was assessed by investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Drug Plasma Concentration (Cmax) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A","description":"Cmax: Maximum observed drug concentration following an infusion of 60 IU/kg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.8","spread":"14.74"},{"groupId":"OG001","value":"177.1","spread":"20.98"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A","description":"AUC: The total area under the plasma concentration versus time curve following an infusion of 60 IU/kg .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3707.5","spread":"33.77"},{"groupId":"OG001","value":"4130.8","spread":"28.8"}]}]}]},{"type":"SECONDARY","title":"Terminal Elimination Half Life (t1/2) Following Single and Multiple Doses of BAY94-9027, Chromogenic Assay - Part A","description":"t1/2: Terminal half-life is the time the plasma concentration during terminal phase is halved following an infusion of 60 IU/kg .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":"27.05"},{"groupId":"OG001","value":"19.6","spread":"38.48"}]}]}]},{"type":"SECONDARY","title":"Overall Human Coagulation Factor VIII (FVIII) Recovery Value by Chromogenic Assay - Part A","description":"Recovery was calculated by the following formula: Recovery = (post-infusion FVIII activity - pre-infusion FVIII activity ) \\* weight / dose (in IU). Recovery is the increase of FVIII activity after the injection normalized by dose: IU/dl per IU/kg = kg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.67","spread":"0.54"},{"groupId":"OG001","value":"2.68","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life by Hemophilia Specific Quality of Life Instrument or Questionnaire for Adults (Haemo-QoL-A) Overall Score at Week 36 - Part A","description":"Quality of life (QoL) was measured by the Haemo-QoL-A overall score, which ranged from 0 (the worst condition) to 100 (the best condition).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"9.70"},{"groupId":"OG001","value":"2.59","spread":"7.98"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Overall Pain Severity and Interference Due to Pain at Week 36 - Part A","description":"Brief Pain Inventory (BPI) - Short Form (BPI-SF) was a 15-item, self-administered, validated tool developed to assess pain used in the study for patient reported outcomes. Scores ranged from 0 to 10 and a higher score indicates a higher level of pain/interference.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.8"},{"groupId":"OG001","value":"0.1","spread":"1.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"2.54"},{"groupId":"OG001","value":"-0.06","spread":"1.39"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 36 - Part A","description":"The WPAI is a validated instrument to assess the effect of hemophilia on ability to work, attend classes, and perform regular daily activities in participants aged 12 and above. The WPAI also contained classroom impairment questions (CIQ). The questionnaire was self-administered and comprised of nine questions that elicited information on work, classroom, and daily activity impairment during the previous seven days. WPAI outcomes that are overall work and activity impairment, transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.74","spread":"24.12"},{"groupId":"OG001","value":"-7.13","spread":"20.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.44","spread":"21.94"},{"groupId":"OG001","value":"-1.22","spread":"21.94"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Recombinant Human Factor VIII (rFVIII) Usage Expressed as Number of Infusions- Part A","description":"For prophylaxis patients, the dose is related to all infusions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"56.0","spread":null},{"groupId":"OG002","value":"55.0","spread":null},{"groupId":"OG003","value":"38.0","spread":null},{"groupId":"OG004","value":"27.0","spread":null},{"groupId":"OG005","value":"37.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Recombinant Human Factor VIII (rFVIII) Usage Expressed as Dose Per Kilogram With Prophylaxis Treatment - Part A","description":"For prophylaxis patients, the dose per kilogram is related to prophylaxis infusions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1986.9","spread":null},{"groupId":"OG001","value":"1669.1","spread":null},{"groupId":"OG002","value":"1704.3","spread":null},{"groupId":"OG003","value":"1530.2","spread":null},{"groupId":"OG004","value":"1644.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Minor Surgeries According to Physician's Assessment of Adequacy of Hemostasis - Part A","description":"Minor surgery was defined as any surgical procedure that did not meet the definition of major, and included simple dental extractions, incision and drainage of abscesses, or simple excisions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Surgeries According to Physician's Assessment of Response to Hemostasis, Post-surgery - Part B Main Trial","description":"Response to treatment during surgery was assessed by investigator/surgeon as excellent, good, moderate, poor or missing during Part B of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Change/Drop in Hemoglobin/Hematocrit Laboratory Assessments - Part B","description":"Hematocrit is defined as the volume percentage (%) of red blood cells in blood.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Maximum Blood Loss During Major Surgery - Part B","description":"Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1000","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Took Anti-fibrinolytic Medications During Major Surgery - Part B","description":"Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Volume of Blood Transfused in Major Surgery - Part B","description":"Major surgery was defined as any surgical or invasive procedure (elective or emergent) in which the overall bleeding risk was excessive, required a general anesthetic in an individual without a bleeding disorder, penetrated or exposed a major body cavity, resulted in substantial impairment of physical or physiological functions, or required special anatomic knowledge or manipulative skill.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"865","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":134},"commonTop":["Nasopharyngitis","Arthralgia","Headache","Back pain","Procedural pain"]}}}